Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
about
How do patients with inflammatory bowel disease want their biological therapy administered?A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea.The placebo effect in irritable bowel syndrome trials: a meta-analysis.Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.Development of a questionnaire to assess patient satisfaction with allergen-specific immunotherapy in adults: item generation, item reduction, and preliminary validation.Targeted therapies for diarrhea-predominant irritable bowel syndrome.Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Osteoporosis medication profile preference: results from the PREFER-US studyRandomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.The trials and tribulations of drug development for functional gastrointestinal disorders.Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome.A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.Patient satisfaction after gut-directed hypnotherapy in irritable bowel syndrome.
P2860
Q33523157-6B8BFC5D-8C2F-48F5-BBE2-4EA48444BBE1Q34237231-2B0FB33C-98CD-4D5B-AC54-2AED23B8CC9FQ34421382-F7E1FC11-B74C-4690-8BC4-ED7B4D26233DQ34552742-D5257D3D-A9F7-419E-B687-BE49A6599889Q35018998-5B917300-7E42-48F5-A27C-6E5116B90166Q36065945-D56FEC52-4933-4F7D-B611-6D0D91FB96ABQ36065990-B981D632-515F-4578-832E-3B786E961ED6Q36088579-6FC80CFD-A4E7-401E-BD14-E0EF3E9A3BDCQ36297736-5AD2972C-EB97-4FBF-BB66-3B1D1DCBCD95Q36983944-984319D0-BBDE-4261-BD00-4AE7BF4C9047Q37134572-5C441284-023A-42FB-B568-666F4CEE6F4FQ38630721-19C8A786-6AE3-488B-AFEB-3350030F6A57Q39267149-964150FD-6E5A-4036-BB6D-6CD7AB73EECBQ39335358-77F5C0F5-ACBF-4793-8DFB-490671303F47Q43171523-0E839EA2-A524-486A-B98F-D5980EA9C8E9Q48375402-4A76E702-4483-4E53-A23C-C7FD395DA384
P2860
Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Patient satisfaction with alos ...... nant irritable bowel syndrome.
@en
Patient satisfaction with alos ...... nant irritable bowel syndrome.
@nl
type
label
Patient satisfaction with alos ...... nant irritable bowel syndrome.
@en
Patient satisfaction with alos ...... nant irritable bowel syndrome.
@nl
prefLabel
Patient satisfaction with alos ...... nant irritable bowel syndrome.
@en
Patient satisfaction with alos ...... nant irritable bowel syndrome.
@nl
P2093
P2860
P1476
Patient satisfaction with alos ...... nant irritable bowel syndrome.
@en
P2093
Adnan Dahdul
Barbara Bagby
Chris Decker
Douglas Young
Enrique DeCastro
Eric Carter
Gary Poleynard
Gregory Mula
John Johanson
Kevin Olden
P2860
P304
P356
10.1111/J.1572-0241.2002.07111.X
P407
P577
2002-12-01T00:00:00Z